CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands |
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Revenues: |
|
|
| Total revenues |
$ 111,014
|
$ 106,275
|
| Costs and expenses: |
|
|
| Cost of sales |
15,832
|
19,872
|
| Research and development expenses |
0
|
4,213
|
| Selling, general and administrative expenses |
56,555
|
104,324
|
| Amortization of intangible assets |
28,114
|
24,783
|
| Loss on impairment of goodwill |
0
|
17,432
|
| Restructuring charges |
1,089
|
17,806
|
| Total costs and expenses |
101,590
|
188,430
|
| Income (loss) from operations |
9,424
|
(82,155)
|
| Other (expense) income: |
|
|
| Interest expense |
(10,220)
|
(15,926)
|
| Other gain (loss) |
243
|
(3,225)
|
| Loss on debt extinguishment |
0
|
(56,113)
|
| Total other (expense) income |
(9,977)
|
36,642
|
| Net loss before income taxes |
(553)
|
(45,513)
|
| Income tax (expense) benefit |
(728)
|
17,369
|
| Net loss |
(1,281)
|
(28,144)
|
| Comprehensive loss |
$ (1,281)
|
$ (28,144)
|
| Basic net loss per share (in dollars per share) |
$ (0.03)
|
$ (1.07)
|
| Diluted net loss per share (in dollars per share) |
$ (0.03)
|
$ (1.07)
|
| Shares used in computing basic net loss per share (in shares) |
43,169
|
26,209
|
| Shares used in computing diluted net loss per share (in shares) |
43,169
|
26,209
|
| Product sales, net |
|
|
| Revenues: |
|
|
| Total revenues |
$ 109,420
|
$ 92,090
|
| Commercialization agreement, net |
|
|
| Revenues: |
|
|
| Total revenues |
0
|
11,258
|
| Royalties and milestones |
|
|
| Revenues: |
|
|
| Total revenues |
2,579
|
1,519
|
| Other revenue |
|
|
| Revenues: |
|
|
| Total revenues |
(985)
|
1,408
|
| NUCYNTA |
|
|
| Other (expense) income: |
|
|
| Gain (loss) on sale |
0
|
(14,749)
|
| Gralise |
|
|
| Other (expense) income: |
|
|
| Gain (loss) on sale |
$ 0
|
$ 126,655
|